Is sirolimus a nephrotoxic drug? A report of five cases

Autor: A.E. Elagroudy, M.A.A. El-Rahim, K.F. El-dahshan, Alaa Sabry, M.A. Sobh
Rok vydání: 2006
Předmět:
Zdroj: Transplantation proceedings. 39(5)
ISSN: 0041-1345
Popis: HE CHOICE OF immunosuppression after organ transplantation is expanding. The past decade has seen the introduction of tacrolimus, mycophenolate mofetil (MMF), and an array of monoclonal antibodies. 1 Calcineurin inhibitors have been a cornerstone of transplant immunosuppression, beginning with the introduction of cyclosporine in 1978 and then tacrolimus in 1989, but nephrotoxicity limits their therapeutic benefit. 2 With the addition of mycophenolate mofetil in 1991, 1-year kidney graft survival rates have improved to greater than 90%. 3 Rapamycin (Rapa) is a new immunosuppressive medication that prolongs allograft survival. It was initially investigated as an antifungal and antitumor agent; however, its lymphopenic properties heralded its role as an immunosuppressant agent. The therapeutic effects of Rapa are derived from the inhibition of proliferation of fibroblasts, endothelial, mesangial and smooth muscle cells. 4 Sirolimus binds to the immunophilin FK506-binding protein-12 with greater avidity than tacrolimus. Animal studies have shown that sirolimus and tacrolimus act synergistically to prevent rejection. 5 Herein we have presented five cases of focal segmental glomerulosclerosis (FSGS) in Egyptian renal transplant patients; both de novo and recurrent FSGS were associated with sirolimus-based immunosuppression.
Databáze: OpenAIRE